We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Analytical Cannabis is no longer active

You have been redirected to the website of Analytical Cannabis’ parent publication, Technology Networks. Here, you’ll find content covering a range of topics across the life sciences, applied markets, analytical sciences, drug discovery and more.

Cannabis Edibles Can Ease Pain and Improve Sleep For Cancer Patients, Study Finds

A cannabis edibles in the shape of a leaf.
Image credit: iStock
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 4 minutes

Over-the-counter cannabis products can help cancer patients manage their symptoms and the side effect of chemotherapy, according to a new study.

Published in Exploration in Medicine, the study assessed 25 cancer patients in Colorado who were asked to buy and consume their own legal cannabis edibles.

After two weeks of cannabis use, the patients reported significant improvements in their sleep and cognition as well as reductions in their levels of pain.

Cannabis for chemo in Colorado

To begin their study, the researchers from the University of Colorado, Boulder, recruited 25 cancer patients via ads in oncology clinics and posts on social media. The patients’ cancers ranged from lung to colon, to brain and breast.

Prior to their cannabis use, all participants completed a survey to assess their levels of sleep quality, psychological functioning, pain intensity, and overall quality of life.

The 25 patients were then asked to buy their own edible cannabis products – the quantity was up to them – from state retailers and consume the edibles at their own leisure. The products ranged across 18 brands and included chocolates, gummies, and tinctures with a variety of THC:CBD ratios.

After two weeks of cannabis use, the participants completed another survey. The research team then compared the results from both questionnaires.

They found that participants experienced, on average, a significant boost in sleep quality, especially those that consumed CBD-rich edibles.

High-CBD products also seemed to treat the pain many patients were experiencing; the participants who used CBD-rich products reported steeper reductions in pain intensity.

To their surprise, the researchers also observed a significant boost in the patients’ perceived cognitive abilities.

“We thought we might see some problems with cognitive function,” Angela Bryan, a professor of psychology and neuroscience at the University of Colorado, Boulder, and co-author of the study, said in a statement.

“But people actually felt like they were thinking more clearly. It was a surprise.”

Bryan and her colleagues have linked the participants’ gains in cognition to their reductions in pain; the more people’s pain subsided, the more their thinking seemed to improve.

Other survey measurements didn’t change much post-edibles, however. The participants reported no significant differences in their quality of life, for instance, and the edibles’ effects on anxiety and depression were considered marginal.

Overall, though, Bryan and her colleagues concluded that over-the-counter edibles could provide a significant benefit to cancer patients experiencing pain and poor sleep. They say further, more rigorous studies will be needed to confirm this conclusion, however.

“We know oncologists and patients are concerned about the possible negative impact of cancer treatment on cognitive function, so the potential, indirect role of cannabis use on improving subjective cognitive function should be studied further,” Gregory Giordano, a professional research assistant at the University of Colorado, Boulder, and lead author of the study, said in a statement.

Cannabis and cancer pain

The Boulder study is thought to be one of the first to measure the effects of commercially available cannabis products; most cannabis-cancer studies use clinical cannabinoid formulations – and these studies have come to conflicting conclusions.

One systematic review of six randomized controlled trials, published in 2020, found that cannabinoid formulations were no different to placebos when it came to changing cancer patients’ average pain scores.

“I think there is great interest in cannabinoid medicines from the general public at the moment,” Mike Bennett, a professor of palliative medicine at the University of Leeds and co-author of that review, told Analytical Cannabis at the time. “But in cancer pain, using this particular product, we can’t see a positive benefit.”

Bennett did hint at the time, however, that other kinds of cannabis products – other than the medical-grade extracts used in the six trials – may offer a benefit to cancer patients.

“So, I think for now, the evidence doesn’t support these cannabinoid medicines for the management of cancer pain. But I can imagine that more research using different sorts of cannabinoid products and different outcome measures might need to be done to me more certain.”